-
(3-((2-Methylindolin-1-yl)sulfonyl)phenyl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone
-
BD01156136749868-66-498%
-
¥3056.0250mg
-
3-((5-Chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one
-
BD6324001383450-81-498%
-
¥330.05mg
-
1'-((5-(Aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one
-
BD011916611903763-82-598%
-
¥883.010mg
-
1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-1,2,4-triazole-3-carboxamide
-
BD538736791-04-598%
-
¥49.025g
-
Ethyl 2-(3-(4-methylpiperidin-1-yl)propanamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
-
BD01180085381731-49-398%
-
¥906.010mg
-
N-(4-(Bis(4-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dien-1-ylidene)-N-methylmethanaminium chloride
-
BD122447548-62-990%
-
¥44.025g
-
N-(2-Hydroxyethyl)-4-methoxy-N-methyl-3-(6-methyl-[1,2,4]triazolo[3,4-a]phthalazin-3-yl)benzenesulfonamide
-
BD01125027861139-16-499%
-
¥1006.010mg
-
RSV/IAV-IN-2
-
BD014702432395007-75-598%
-
¥
-
RSV-IN-5
-
BD015781182415018-86-798%
-
¥
-
Suptavumab
-
BD018254311629615-23-195%
-
¥
-
4-Hydroxy-2-methylbenzenesulfonic acid ammonium
-
BD0149168598%
-
¥
-
JNJ 2408068
-
BD01581028317846-22-398%
-
¥
-
RSV-IN-6
-
BD015762242415152-41-798%
-
¥
-
Motavizumab
-
BD01595026677010-34-398%
-
¥
-
OUN58101
-
BD01852681851658-10-198%
-
¥
-
RSV/IAV-IN-1
-
BD015166282395007-77-798%
-
¥
-
Palivizumab
-
BD01605688188039-54-598%
-
¥
-
1'-((5-(Aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one hydrochloride
-
BD013775681903763-83-698%
-
¥